Regulus Therapeutics (NASDAQ:RGLS) Earns Hold Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report report published on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock. RGLS has been the topic of several other reports. HC Wainwright reissued a buy rating and issued a $9.00 price target on shares of […]
More Stories
Trump Says Minnesota Officials Will Face ‘Day of Reckoning’ Amid Protests
By Jack Phillips President Donald Trump on Tuesday warned that state officials in Minnesota would face a “DAY OF RECKONING...
US Holiday Spending Jumped in December, Signaling Consumer Strength Into 2026
By Tom Ozimek American consumers closed out the holiday season with a strong December spending surge, adding to evidence that...
US Embassy Warns American Citizens Still in Iran to Leave ‘Now’
By Jack Phillips The U.S. State Department on Monday evening sent a warning to any Americans who are still remaining...
House Panel to Initiate Contempt Proceedings Against Bill Clinton, Comer Says
By Nathan Worcester WASHINGTON—House Oversight Committee Chairman James Comer (R-Ky.) said that his committee will move to hold President Bill...
Pentagon Injects $1 Billion Into L3Harris to Boost Missile Motor Output
By Tom Ozimek The U.S. government will invest $1 billion in L3Harris Technologies’ rocket motor business, a rare direct-to-supplier partnership...
Top Miro Alternatives in 2026 | Free Competitors of Miro for Startups
Looking for an alternative to Miro? Don’t worry, I’ll share a list of tools that are better than Miro. This...